BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Q3 2024 Earnings Conference Call October 29, 2024 4:30 PM ET
Company Participants
Traci McCarty - Head of Investor Relations
Alexander Hardy - President and Chief Executive Officer
Brian Mueller - Executive Vice President and Chief Financial Officer
Cristin Hubbard - Executive Vice President and Chief Commercial Officer
Greg Friberg - Executive Vice President and Chief Research & Development Officer
Conference Call Participants
Philip Nadeau - TD Cowen
Salveen Richter - Goldman Sachs
Jessica Fye - JPMorgan
Paul Matteis - Stifel
Eli Merle - UBS
Cory Kasimov - Evercore
Kostas Biliouris - BMO Capital Markets
Joseph Schwartz - Leerink Partners
Akash Tewari - Jefferies
Christopher Raymond - Piper Sandler
Mohit Bansal - Wells Fargo
John Wang - Barclays
Operator
Thank you for standing by. My name is Bailey and I will be your conference operator today. At this time, I would like to welcome everyone to the BioMarin Pharmaceuticals third quarter 2024 conference call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question-and-answer session. [Operator Instructions]
I would now like to turn the call over to Traci McCarty, Group Vice President of Investor Relations. You may begin.
Traci McCarty
Thank you, Operator. To remind you, this non-confidential presentation contains forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc., including expectations regarding BioMarin's financial performance, commercial products and potential future products in different areas of therapeutic search and development. Results may differ materially depending on the progress of BioMarin's product programs, actions of regulatory authorities, availability of capital, future actions in the pharmaceutical market and developments by competitors and those factors detailed in BioMarin's filings with the Securities and Exchange Commission, such as 10-Q, 10-K and 8-K reports.
In addition, we will use non-GAAP financial measures as defined in Regulation G during the call today. These non-GAAP measures should not be considered in isolation from, as substitutes for or superior to financial measures prepared in accordance with U.S. GAAP, and you can find the related reconciliations to U.S. GAAP in the earnings release and earnings presentation, both of which are available in the Investor Relations section of our website.
On the call from BioMarin management today are Alexander Hardy, President and Chief Executive Officer; Brian Mueller, Executive Vice President, Chief Financial Officer; Cristin Hubbard, Executive Vice President, Chief Commercial Officer; and Greg Friberg, Executive Vice President, Worldwide R&D.